Abstract

Review Article

A General Evaluation of the Cellular Role in Drug Release: A Clinical Review Study

Mohammad Hossein Karami* and Majid Abdouss*

Published: 26 March, 2024 | Volume 7 - Issue 1 | Pages: 042-050

Cells have emerged as highly promising vehicles for delivering drugs due to their unique advantages. They have the ability to bypass immune recognition, navigate biological barriers, and reach difficult-to-access tissues through sensing and active movement. Over the past couple of decades, extensive research has been conducted to understand how cell carriers can overcome biological barriers and influence drug effectiveness. This has resulted in the development of engineered cells for targeted drug delivery to specific tissues. Despite the presence of exciting developments, a comprehensive understanding of the challenges and potential strategies is necessary for the effective clinical application of cell-based drug carriers. This review provides an overview of recent progress and novel concepts in cell-based drug carriers, as well as their potential for translation into clinical practice. Additionally, we delve into important factors and emerging strategies for designing the next generation of cell-based delivery technologies, with a particular emphasis on achieving greater accuracy and targeted drug administration.

Read Full Article HTML DOI: 10.29328/journal.cjog.1001162 Cite this Article Read Full Article PDF

Keywords:

Drug delivery; Nanoparticles; Cell-based drug delivery; Cell trafficking; Cell homing

References

  1. Tewabe A, Abate A, Tamrie M, Seyfu A, Abdela Siraj E. Targeted Drug Delivery - From Magic Bullet to Nanomedicine: Principles, Challenges, and Future Perspectives. J Multidiscip Healthc. 2021 Jul 5;14:1711-1724. doi: 10.2147/JMDH.S313968. PMID: 34267523; PMCID: PMC8275483.
  2. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015 Sep;33(9):941-51. doi: 10.1038/nbt.3330. PMID: 26348965; PMCID: PMC4978509.
  3. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;
  4. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2016 Jun 3;1(1):10-29. doi: 10.1002/btm2.10003. PMID: 29313004; PMCID: PMC5689513.
  5. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011 Mar 18;63(3):131-5. doi: 10.1016/j.addr.2010.03.011. Epub 2010 Mar 18. PMID: 20304019.
  6. Zhao Z, Ukidve A, Krishnan V, Mitragotri S. Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers. Adv Drug Deliv Rev. 2019 Mar 15;143:3-21. doi: 10.1016/j.addr.2019.01.002. Epub 2019 Jan 11. PMID: 30639257.
  7. Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10980-5. doi: 10.1073/pnas.1106634108. Epub 2011 Jun 20. PMID: 21690347; PMCID: PMC3131364.
  8. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008 Dec;8(12):958-69. doi: 10.1038/nri2448. Erratum in: Nat Rev Immunol.2010 Jun;10(6):460. PMID: 19029990; PMCID: PMC2724991.
  9. Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting Strategies for Tissue-Specific Drug Delivery. Cell. 2020 Apr 2;181(1):151-167. doi: 10.1016/j.cell.2020.02.001. PMID: 32243788.
  10. Li ZT, Wang YX, Ding YY, Repp L, Kwon GS, Hu QY. Cell-Based Delivery Systems: Emerging Carriers for Immunotherapy, Adv. Funct. Mater. 2021; 31.
  11. Marano L, Verre L, Carbone L, Poto GE, Fusario D, Venezia DF, Calomino N, Kaźmierczak-Siedlecka K, Polom K, Marrelli D, Roviello F, Kok JHH, Vashist Y. Current Trends in Volume and Surgical Outcomes in Gastric Cancer. J Clin Med. 2023 Apr 4;12(7):2708. doi: 10.3390/jcm12072708. PMID: 37048791; PMCID: PMC10094776.
  12. Yang L, Yang Y, Chen Y, Xu Y, Peng J. Cell-based drug delivery systems and their in vivo fate. Adv Drug Deliv Rev. 2022 Aug;187:114394. doi: 10.1016/j.addr.2022.114394. Epub 2022 Jun 17. PMID: 35718252.
  13. Glassman PM, Hood ED, Ferguson LT, Zhao Z, Siegel DL, Mitragotri S, Brenner JS, Muzykantov VR. Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers. Adv Drug Deliv Rev. 2021 Nov;178:113992. doi: 10.1016/j.addr.2021.113992. Epub 2021 Sep 29. PMID: 34597748; PMCID: PMC8556370.
  14. Brenner JS, Mitragotri S, Muzykantov VR. Red Blood Cell Hitchhiking: A Novel Approach for Vascular Delivery of Nanocarriers. Annu Rev Biomed Eng. 2021 Jul 13;23:225-248. doi: 10.1146/annurev-bioeng-121219-024239. Epub 2021 Mar 31. PMID: 33788581; PMCID: PMC8277719.
  15. Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017 Jan 25;9(374):eaaj2013. doi: 10.1126/scitranslmed.aaj2013. Erratum in: Sci Transl Med. 2017 Feb 15;9(377):null. PMID: 28123068.
  16. Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S, Deuse T. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression, Nature. Biotechnology.
  17. Pandey PK, Sharma AK, Gupta U. Blood brain barrier: An overview on strategies in drug delivery, realistic in vitro modeling and in vivo live tracking. Tissue Barriers. 2015 Dec 15;4(1):e1129476. doi: 10.1080/21688370.2015.1129476. PMID: 27141418; PMCID: PMC4836458.
  18. Afergan E, Epstein H, Dahan R, Koroukhov N, Rohekar K, Danenberg HD, Golomb G. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release. 2008 Dec 8;132(2):84-90. doi: 10.1016/j.jconrel.2008.08.017. Epub 2008 Sep 4. PMID: 18805446.
  19. Karami MH, Abdouss M, Rahdar A, Pandey A. Graphene quantum dots: background, synthesis methods, and applications as nanocarrier in drug delivery and cancer treatment: an updated review. Inorg Chem Commun. 2024; 161:112032.
  20. Bhan A, Ansari K, Chen MY, Jandial R. Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain. Sci Rep. 2021 Oct 15;11(1):16866. doi: 10.1038/s41598-021-96351-2. Retraction in: Sci Rep. 2024 Mar 12;14(1):5972. PMID: 34654856; PMCID: PMC8521584.
  21. Kremer V, Ligtenberg MA, Zendehdel R, Seitz C, Duivenvoorden A, Wennerberg E, Colón E, Scherman-Plogell AH, Lundqvist A. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. J Immunother Cancer. 2017 Sep 19;5(1):73. doi: 10.1186/s40425-017-0275-9. Erratum in: J Immunother Cancer. 2017 Nov 6;5(1):88. PMID: 28923105; PMCID: PMC5604543.
  22. Hamadani CM, Goetz MJ, Mitragotri S, Tanner EEL. Protein-avoidant ionic liquid (PAIL)-coated nanoparticles to increase bloodstream circulation and drive biodistribution. Sci Adv. 2020 Nov 25;6(48):eabd7563. doi: 10.1126/sciadv.abd7563. PMID: 33239302; PMCID: PMC7688330.
  23. Blagovic K, Smith CK, Ramakrishnan A, Moore L, Soto DR, Thompson Z, Stockmann AP, Kruszelnicki S, Thakkar A, Murray J, Torres S, Wondimagegnhu B, Yi R, Dadgar M, Paracha AM, Page C, Clear L, Chaudhry OA, Myint M, Bridgen DT, Gilbert JB, Seidl KJ, Sharei A, Loughhead S, Bernstein H, Yarar D. Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice. Front Immunol. 2022 Oct 3;13:1015585. doi: 10.3389/fimmu.2022.1015585. PMID: 36263022; PMCID: PMC9573954.
  24. Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, Qiao Y. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021 Apr 23;6(1):153. doi: 10.1038/s41392-021-00544-0. PMID: 33888679; PMCID: PMC8062524.
  25. Karami MH, Pourmadadi M, Abdouss M, Kalaee MR, Moradi O, Rahdar A, Díez-Pascual AM. Novel chitosan/γ-alumina/carbon quantum dot hydrogel nanocarrier for targeted drug delivery. Int J Biol Macromol. 2023 Aug 15;251:126280. doi: 10.1016/j.ijbiomac.2023.126280. Epub ahead of print. PMID: 37591420.
  26. Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, Liu H, Wang LL, Rowley DR, Pfizenmaier K, Gottschalk S. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013 Aug;21(8):1611-20. doi: 10.1038/mt.2013.110. Epub 2013 Jun 4. PMID: 23732988; PMCID: PMC3734659.
  27. Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, Zheng W, Lu Y, Zhang W, Bei Y, Shen P. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019 Nov;121(10):837-845. doi: 10.1038/s41416-019-0578-3. Epub 2019 Oct 1. PMID: 31570753; PMCID: PMC6889154.
  28. Chu D, Dong X, Zhao Q, Gu J, Wang Z. Photosensitization Priming of Tumor Microenvironments Improves Delivery of Nanotherapeutics via Neutrophil Infiltration. Adv Mater. 2017 Jul;29(27):10.1002/adma.201701021. doi: 10.1002/adma.201701021. Epub 2017 May 15. PMID: 28504320; PMCID: PMC5510494.
  29. Shields CW 4th, Evans MA, Wang LL, Baugh N, Iyer S, Wu D, Zhao Z, Pusuluri A, Ukidve A, Pan DC, Mitragotri S. Cellular backpacks for macrophage immunotherapy. Sci Adv. 2020 Apr 29;6(18):eaaz6579. doi: 10.1126/sciadv.aaz6579. PMID: 32494680; PMCID: PMC7190308.
  30. Karami MH, Abdouss Assessing Particle Size and Surface Charge in Drug Carrier Nanoparticles for Enhanced Cancer Treatment: A Comprehensive Review Utilizing DLS and Zeta Potential Characterization. PSPRJ. 2024; 5(3): 000615.
  31. Karami MH, Abdouss M, Karami M. Evaluation of in vitro and ex vivo models for studying the effectiveness of vaginal drug systems in controlling microbe infections: A systematic review. Clin J Obst Gynecol. 2023; 6: 201-215.
  32. Li J, Ding Y, Cheng Q, Gao C, Wei J, Wang Z, Huang Q, Wang R. Supramolecular erythrocytes-hitchhiking drug delivery system for specific therapy of acute pneumonia. J Control Release. 2022 Oct;350:777-786. doi: 10.1016/j.jconrel.2022.08.029. Epub 2022 Sep 12. PMID: 35995300.
  33. Han X, Wang C, Liu Z. Red Blood Cells as Smart Delivery Systems. Bioconjug Chem. 2018 Apr 18;29(4):852-860. doi: 10.1021/acs.bioconjchem.7b00758. Epub 2018 Jan 22. PMID: 29298380.
  34. Zhang E, Phan P, Algarni HA, Zhao Z. Red Blood Cell Inspired Strategies for Drug Delivery: Emerging Concepts and New Advances. Pharm Res. 2022 Nov;39(11):2673-2698. doi: 10.1007/s11095-022-03328-5. Epub 2022 Jul 7. PMID: 35794397.
  35. Karami MH, Abdouss M. Recent advances of carbon quantum dots in tumor imaging. Nanomed J. 2024; 11(1): 13-35.
  36. Ihler GM, Glew RH, Schnure FW. Enzyme loading of erythrocytes. Proc Natl Acad Sci U S A. 1973 Sep;70(9):2663-6. doi: 10.1073/pnas.70.9.2663. PMID: 4354859; PMCID: PMC427078.
  37. Li Y, Raza F, Liu Y, Wei Y, Rong R, Zheng M, Yuan W, Su J, Qiu M, Li Y, Raza F, Liu Y, Wei Y, Rong R, Zheng M, Yuan W, Su J, Qiu M. Clinical progress and advanced research of red blood cells based drug delivery system. Biomaterials. 2021 Dec;279:121202. doi: 10.1016/j.biomaterials.2021.121202. Epub 2021 Oct 22. PMID: 34749072.
  38. Rossi L, Pierigè F, Aliano MP, Magnani M. Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies. BioDrugs. 2020 Jun;34(3):265-272. doi: 10.1007/s40259-020-00415-0. PMID: 32198632; PMCID: PMC7211199.
  39. Su J, Sun H, Meng Q, Yin Q, Zhang P, Zhang Z, Yu H, Li Y. Bioinspired nanoparticles with NIR-controlled drug release for synergetic chemophotothermal therapy of metastatic breast cancer, Adv. Funct. Mater. 2016; 26: 7495-7506.
  40. Leuzzi V, Micheli R, D'Agnano D, Molinaro A, Venturi T, Plebani A, Soresina A, Marini M, Ferremi Leali P, Quinti I, Pietrogrande MC, Finocchi A, Fazzi E, Chessa L, Magnani M. Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e98. doi: 10.1212/NXI.0000000000000098. PMID: 25884015; PMCID: PMC4396528.
  41. Kontos S, Kourtis IC, Dane KY, Hubbell JA. Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E60-8. doi: 10.1073/pnas.1216353110. Epub 2012 Dec 17. PMID: 23248266; PMCID: PMC3538192.
  42. Pishesha N, Bilate AM, Wibowo MC, Huang NJ, Li Z, Deshycka R, Bousbaine D, Li H, Patterson HC, Dougan SK, Maruyama T, Lodish HF, Ploegh HL. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3157-3162. doi: 10.1073/pnas.1701746114. Epub 2017 Mar 7. Erratum in: Proc Natl Acad Sci U S A. 2017 Apr 25;114(17 ):E3583. Dhesycka, Rhogerry [corrected to Deshycka, Rhogerry]. PMID: 28270614; PMCID: PMC5373388.
  43. Zhao Z, Ukidve A, Gao Y, Kim J, Mitragotri S. Erythrocyte leveraged chemotherapy (ELeCt): Nanoparticle assembly on erythrocyte surface to combat lung metastasis. Sci Adv. 2019 Nov 13;5(11):eaax9250. doi: 10.1126/sciadv.aax9250. PMID: 31763454; PMCID: PMC6853768.
  44. Wang C, Ye Y, Sun W, Yu J, Wang J, Lawrence DS, Buse JB, Gu Z. Red Blood Cells for Glucose-Responsive Insulin Delivery. Adv Mater. 2017 May;29(18). doi: 10.1002/adma.201606617. Epub 2017 Mar 7. PMID: 28267235.
  45. Gao M, Hu A, Sun X, Wang C, Dong Z, Feng L, Liu Z. Photosensitizer Decorated Red Blood Cells as an Ultrasensitive Light-Responsive Drug Delivery System. ACS Appl Mater Interfaces. 2017 Feb 22;9(7):5855-5863. doi: 10.1021/acsami.6b15444. Epub 2017 Feb 7. PMID: 28117965.
  46. Wang P , Jiang S , Li Y , Luo Q , Lin J , Hu L , Xu C , Zhu J , Fan L . Fabrication of hypoxia-responsive and uperconversion nanoparticles-modified RBC micro-vehicles for oxygen delivery and chemotherapy enhancement. Biomater Sci. 2020 Aug 21;8(16):4595-4602. doi: 10.1039/d0bm00678e. Epub 2020 Jul 23. PMID: 32700684.
  47. Anselmo AC, Gupta V, Zern BJ, Pan D, Zakrewsky M, Muzykantov V, Mitragotri S. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano. 2013 Dec 23;7(12):11129-37. doi: 10.1021/nn404853z. Epub 2013 Nov 12. PMID: 24182189; PMCID: PMC4128963.
  48. Brenner JS, Pan DC, Myerson JW, Marcos-Contreras OA, Villa CH, Patel P, Hekierski H, Chatterjee S, Tao JQ, Parhiz H, Bhamidipati K, Uhler TG, Hood ED, Kiseleva RY, Shuvaev VS, Shuvaeva T, Khoshnejad M, Johnston I, Gregory JV, Lahann J, Wang T, Cantu E, Armstead WM, Mitragotri S, Muzykantov V. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude. Nat Commun. 2018 Jul 11;9(1):2684. doi: 10.1038/s41467-018-05079-7. PMID: 29992966; PMCID: PMC6041332.
  49. Zhao Z, Ukidve A, Krishnan V, Fehnel A, Pan DC, Gao Y, Kim J, Evans MA, Mandal A, Guo J, Muzykantov VR, Mitragotri S. Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases. Nat Biomed Eng. 2021 May;5(5):441-454. doi: 10.1038/s41551-020-00644-2. Epub 2020 Nov 16. PMID: 33199847.
  50. Zhao Z, Kim J, Suja VC, Kapate N, Gao Y, Guo J, Muzykantov VR, Mitragotri S. Red Blood Cell Anchoring Enables Targeted Transduction and Re-Administration of AAV-Mediated Gene Therapy. Adv Sci (Weinh). 2022 Aug;9(24):e2201293. doi: 10.1002/advs.202201293. Epub 2022 Jul 3. PMID: 35780495; PMCID: PMC9404386.
  51. Ding Y, Lv B, Zheng J, Lu C, Liu J, Lei Y, Yang M, Wang Y, Li Z, Yang Y, Gong W, Han J, Gao C. RBC-hitchhiking chitosan nanoparticles loading methylprednisolone for lung-targeting delivery. J Control Release. 2022 Jan;341:702-715. doi: 10.1016/j.jconrel.2021.12.018. Epub 2021 Dec 18. PMID: 34933051; PMCID: PMC8684098.
  52. Ferguson LT, Hood ED, Shuvaeva T, Shuvaev VV, Basil MC, Wang Z, Nong J, Ma X, Wu J, Myerson JW, Marcos-Contreras OA, Katzen J, Carl JM, Morrisey EE, Cantu E, Villa CH, Mitragotri S, Muzykantov VR, Brenner JS. Dual Affinity to RBCs and Target Cells (DART) Enhances Both Organ- and Cell Type-Targeting of Intravascular Nanocarriers. ACS Nano. 2022 Mar 22;16(3):4666-4683. doi: 10.1021/acsnano.1c11374. Epub 2022 Mar 10. PMID: 35266686; PMCID: PMC9339245.
  53. Karami MH, M/Abdouss M, Maleki B. The State of the Art Metal Nanoparticles in Drug Delivery Systems: A Comprehensive Review Nanomed J. 2024. Article in press.
  54. Hamadani CM, Goetz MJ, Mitragotri S, Tanner EEL. Protein-avoidant ionic liquid (PAIL)-coated nanoparticles to increase bloodstream circulation and drive biodistribution. Sci Adv. 2020 Nov 25;6(48):eabd7563. doi: 10.1126/sciadv.abd7563. PMID: 33239302; PMCID: PMC7688330.
  55. Blagovic K, Smith C, Ramakrishnan A, Moore L, Soto D, Thompson Z, Stockmann A, Kruszelnicki S, Thakkar A, Murray J, Torres S, Wondimagegnhu B, Yi R, Dadgar M, Paracha A, Page C, Clear L, Chaudhry O, Myint M, Bridgen D, Gilbert J, Seidl K, Sharei A, Loughhead S.
  56. Bernstein H, Yarar D. Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice, Front. Immunol. 2022; 13.
  57. Sun X, Han X, Xu L, Gao M, Xu J, Yang R, Liu Z. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy. Small. 2017 Oct;13(40). doi: 10.1002/smll.201701864. Epub 2017 Sep 1. PMID: 28861943.
  58. Sun L, Shen F, Xu J, Han X, Fan C, Liu Z. DNA-Edited Ligand Positioning on Red Blood Cells to Enable Optimized T Cell Activation for Adoptive Immunotherapy. Angew Chem Int Ed Engl. 2020 Aug 24;59(35):14842-14853. doi: 10.1002/anie.202003367. Epub 2020 Jun 9. PMID: 32395895.
  59. Lorentz KM, Kontos S, Diaceri G, Henry H, Hubbell JA. Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase. Sci Adv. 2015 Jul 17;1(6):e1500112. doi: 10.1126/sciadv.1500112. PMID: 26601215; PMCID: PMC4646778.
  60. Ukidve A, Zhao Z, Fehnel A, Krishnan V, Pan DC, Gao Y, Mandal A, Muzykantov V, Mitragotri S. Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function. Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17727-17736. doi: 10.1073/pnas.2002880117. Epub 2020 Jul 14. PMID: 32665441; PMCID: PMC7395435.
  61. Cremel M, Guérin N, Horand F, Banz A, Godfrin Y. Red blood cells as innovative antigen carrier to induce specific immune tolerance. Int J Pharm. 2013 Feb 25;443(1-2):39-49. doi: 10.1016/j.ijpharm.2012.12.044. Epub 2013 Jan 7. PMID: 23305866.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?